Breast cancer-associated fibroblasts: Where we are and where we need to go

Cancers

Volumn 8, Issue 2, 2016, Pages

  Buchsbaum, Rachel J ^a   Oh, Sun Young ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Cancer associated fibroblasts; Tumor microenvironment

Indexed keywords

ALKYLATING AGENT; ALPHA SMOOTH MUSCLE ACTIN; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC METAL COMPLEX; AROMATASE INHIBITOR; CAVEOLIN 1; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYTOKINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FULVESTRANT; GEFITINIB; MATRIX METALLOPROTEINASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PODOPLANIN; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; SEPRASE; TAMOXIFEN; TAXANE DERIVATIVE; TENASCIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST CARCINOGENESIS; CANCER INHIBITION; CYTOKINE RELEASE; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FIBROBLAST; GENE EXPRESSION PROFILING; HUMAN; LYMPHANGIOGENESIS; METASTASIS; NONHUMAN; NUCLEAR REPROGRAMMING; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REVIEW; TUMOR CELL; TUMOR GROWTH; TUMOR INVASION; TUMOR MICROENVIRONMENT;

EID: 84956954703     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers8020019     Document Type: Review

References (131)

1. Brenton, J.D.; Carey, L.A.; Ahmed, A.A.; Caldas, C. Molecular classification and molecular forecasting of breast cancer: Ready for clinical application? J. Clin. Oncol. 2005, 23, 7350-7360. [CrossRef] [PubMed].
2. Cheang, M.C.; Chia, S.K.; Voduc, D.; Gao, D.; Leung, S.; Snider, J.; Watson, M.; Davies, S.; Bernard, P.S.; Parker, J.S.; et al. Ki67 index, HER2 status, and prognosis of patients with luminal b breast cancer. J. Natl. Cancer Inst. 2009, 101, 736-750. [CrossRef] [PubMed].
3. Parker, J.S.; Mullins, M.; Cheang, M.C.; Leung, S.; Voduc, D.; Vickery, T.; Davies, S.; Fauron, C.; He, X.; Hu, Z.; et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 2009, 27, 1160-1167. [CrossRef] [PubMed].
4. Rakha, E.A.; Reis-Filho, J.S.; Ellis, I.O. Basal-like breast cancer: A critical review. J. Clin. Oncol. 2008, 26, 2568-2581. [CrossRef] [PubMed].
5. Voduc, K.D.; Cheang, M.C.; Tyldesley, S.; Gelmon, K.; Nielsen, T.O.; Kennecke, H. Breast cancer subtypes and the risk of local and regional relapse. J. Clin. Oncol. 2010, 28, 1684-1691. [CrossRef] [PubMed].
6. Quail, D.F.; Joyce, J.A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 2013, 19, 1423-1437. [CrossRef] [PubMed].
7. Kalluri, R.; Zeisberg, M. Fibroblasts in cancer. Nat. Rev. Cancer 2006, 6, 392-401. [CrossRef] [PubMed].
8. Tomasek, J.J.; Gabbiani, G.; Hinz, B.; Chaponnier, C.; Brown, R.A. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat. Rev. Mol. Cell. Biol. 2002, 3, 349-363. [CrossRef] [PubMed].
9. Chaponnier, C.; Gabbiani, G. Pathological situations characterized by altered actin isoform expression. J. Pathol. 2004, 204, 386-395. [CrossRef] [PubMed].
10. Luo, H.; Tu, G.; Liu, Z.; Liu, M. Cancer-associated fibroblasts: A multifaceted driver of breast cancer progression. Cancer Lett. 2015, 361, 155-163. [CrossRef] [PubMed].
11. Mao, Y.; Keller, E.T.; Garfield, D.H.; Shen, K.;Wang, J. Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev. 2013, 32, 303-315. [CrossRef] [PubMed].
12. Dvorak, H.F. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 1986, 315, 1650-1659. [PubMed].
13. Sappino, A.P.; Skalli, O.; Jackson, B.; Schurch, W.; Gabbiani, G. Smooth-muscle differentiation in stromal cells of malignant and non-malignant breast tissues. Int. J. Cancer 1988, 41, 707-712. [CrossRef] [PubMed].
14. Dabiri, S.; Talebi, A.; Shahryari, J.; Meymandi, M.S.; Safizadeh, H. Distribution of myofibroblast cells and microvessels around invasive ductal carcinoma of the breast and comparing with the adjacent range of their normal-to-DCIS zones. Arch. Iran. Med. 2013, 16, 93-99. [PubMed].
15. Surowiak, P.; Murawa, D.; Materna, V.; Maciejczyk, A.; Pudelko, M.; Ciesla, S.; Breborowicz, J.; Murawa, P.; Zabel, M.; Dietel, M.; et al. Occurence of stromal myofibroblasts in the invasive ductal breast cancer tissue is an unfavourable prognostic factor. Anticancer Res. 2007, 27, 2917-2924. [PubMed].
16. Yamashita, M.; Ogawa, T.; Zhang, X.; Hanamura, N.; Kashikura, Y.; Takamura, M.; Yoneda, M.; Shiraishi, T. Role of stromal myofibroblasts in invasive breast cancer: Stromal expression of alpha-smooth muscle actin correlates with worse clinical outcome. Breast Cancer (Tokyo, Japan) 2012, 19, 170-176. [CrossRef] [PubMed].
17. Yazhou, C.;Wenlv, S.;Weidong, Z.; Licun,W. Clinicopathological significance of stromal myofibroblasts in invasive ductal carcinoma of the breast. Tumour Biol. 2004, 25, 290-295. [CrossRef] [PubMed].
18. Bouras, T.; Lisanti, M.P.; Pestell, R.G. Caveolin-1 in breast cancer. Cancer Biol. Ther. 2004, 3, 931-941. [CrossRef] [PubMed].
19. El-Gendi, S.M.; Mostafa, M.F.; El-Gendi, A.M. Stromal caveolin-1 expression in breast carcinoma. Correlation with early tumor recurrence and clinical outcome. Pathol. Oncol. Res. 2012, 18, 459-469. [CrossRef] [PubMed].
20. Mercier, I.; Casimiro, M.C.; Wang, C.; Rosenberg, A.L.; Quong, J.; Minkeu, A.; Allen, K.G.; Danilo, C.; Sotgia, F.; Bonuccelli, G.; et al. Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy. Cancer Biol. Ther. 2008, 7, 1212-1225. [CrossRef] [PubMed].
21. Ren, M.; Liu, F.; Zhu, Y.; Li, Y.; Lang, R.; Fan, Y.; Gu, F.; Zhang, X.; Fu, L. Absence of caveolin-1 expression in carcinoma-associated fibroblasts of invasive micropapillary carcinoma of the breast predicts poor patient outcome. Virchows Arch. 2014, 465, 291-298. [CrossRef] [PubMed].
22. Sloan, E.K.; Ciocca, D.R.; Pouliot, N.; Natoli, A.; Restall, C.; Henderson, M.A.; Fanelli, M.A.; Cuello-Carrion, F.D.; Gago, F.E.; Anderson, R.L. Stromal cell expression of caveolin-1 predicts outcome in breast cancer. Am. J. Pathol. 2009, 174, 2035-2043. [CrossRef] [PubMed].
23. Trimmer, C.; Sotgia, F.; Whitaker-Menezes, D.; Balliet, R.M.; Eaton, G.; Martinez-Outschoorn, U.E.; Pavlides, S.; Howell, A.; Iozzo, R.V.; Pestell, R.G.; et al. Caveolin-1 and mitochondrial SOD2 (MnSOD) function as tumor suppressors in the stromal microenvironment: A new genetically tractable model for human cancer-associated fibroblasts. Cancer Biol. Ther. 2011, 11, 383-394. [CrossRef] [PubMed].
24. Witkiewicz, A.K.; Dasgupta, A.; Sammons, S.; Er, O.; Potoczek, M.B.; Guiles, F.; Sotgia, F.; Brody, J.R.; Mitchell, E.P.; Lisanti, M.P. Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. Cancer Biol. Ther. 2010, 10, 135-143. [CrossRef] [PubMed].
25. Witkiewicz, A.K.; Dasgupta, A.; Sotgia, F.; Mercier, I.; Pestell, R.G.; Sabel, M.; Kleer, C.G.; Brody, J.R.; Lisanti, M.P. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am. J. Pathol. 2009, 174, 2023-2034. [CrossRef] [PubMed].
26. Ariga, N.; Sato, E.; Ohuchi, N.; Nagura, H.; Ohtani, H. Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast. Int. J. Cancer 2001, 95, 67-72. [CrossRef].
27. Ioachim, E.; Charchanti, A.; Briasoulis, E.; Karavasilis, V.; Tsanou, H.; Arvanitis, D.L.; Agnantis, N.J.; Pavlidis, N. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type iv and laminin in breast cancer: Their prognostic value and role in tumour invasion and progression. Eur. J. Cancer 2002, 38, 2362-2370. [CrossRef].
28. Ishihara, A.; Yoshida, T.; Tamaki, H.; Sakakura, T. Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. Clin. Cancer Res. 1995, 1, 1035-1041. [PubMed].
29. Iskaros, B.F.; Hu, X.; Sparano, J.A.; Fineberg, S.A. Tenascin pattern of expression and established prognostic factors in invasive breast carcinoma. J. Surg. Oncol. 1998, 68, 107-112. [CrossRef].
30. Breiteneder-Geleff, S.; Soleiman, A.; Kowalski, H.; Horvat, R.; Amann, G.; Kriehuber, E.; Diem, K.; Weninger, W.; Tschachler, E.; Alitalo, K.; et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: Podoplanin as a specific marker for lymphatic endothelium. Am. J. Pathol. 1999, 154, 385-394. [CrossRef].
31. Dang, Q.; Liu, J.; Li, J.; Sun, Y. Podoplanin: A novel regulator of tumor invasion and metastasis. Med. Oncol. 2014, 31, 24. [CrossRef] [PubMed].
32. Niemiec, J.A.; Adamczyk, A.; Ambicka, A.; Mucha-Malecka, A.; M.Wysocki,W.; Rys, J. Triple-negative, basal marker-expressing, and high-grade breast carcinomas are characterized by high lymphatic vessel density and the expression of podoplanin in stromal fibroblasts. Appl. Immunohistochem. Mol. Morphol. 2014, 22, 10-16. [CrossRef] [PubMed].
33. Pula, B.; Jethon, A.; Piotrowska, A.; Gomulkiewicz, A.; Owczarek, T.; Calik, J.;Wojnar, A.;Witkiewicz,W.; Rys, J.; Ugorski, M.; et al. Podoplanin expression by cancer-associated fibroblasts predicts poor outcome in invasive ductal breast carcinoma. Histopathology 2011, 59, 1249-1260. [CrossRef] [PubMed].
34. Pula, B.; Wojnar, A.; Werynska, B.; Ambicka, A.; Kruczak, A.; Witkiewicz, W.; Ugorski, M.; Podhorska-Okolow, M.; Dziegiel, P. Impact of different tumour stroma assessment methods regarding podoplanin expression on clinical outcome in patients with invasive ductal breast carcinoma. Anticancer Res. 2013, 33, 1447-1455. [PubMed].
35. Schoppmann, S.F.; Berghoff, A.; Dinhof, C.; Jakesz, R.; Gnant, M.; Dubsky, P.; Jesch, B.; Heinzl, H.; Birner, P. Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer. Breast Cancer Res. Treat. 2012, 134, 237-244. [CrossRef] [PubMed].
36. Ostman, A.; Heldin, C.H. PDGF receptors as targets in tumor treatment. Adv. Cancer Res. 2007, 97, 247-274. [PubMed].
37. Paulsson, J.; Sjoblom, T.; Micke, P.; Ponten, F.; Landberg, G.; Heldin, C.H.; Bergh, J.; Brennan, D.J.; Jirstrom, K.; Ostman, A. Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am. J. Pathol. 2009, 175, 334-341. [CrossRef] [PubMed].
38. Weigel, M.T.; Banerjee, S.; Arnedos, M.; Salter, J.; A'Hern, R.; Dowsett, M.; Martin, L.A. Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer. Ann. Oncol. 2013, 24, 126-133. [CrossRef] [PubMed].
39. Folgueira, M.A.; Maistro, S.; Katayama, M.L.; Roela, R.A.; Mundim, F.G.; Nanogaki, S.; de Bock, G.H.; Brentani, M.M. Markers of breast cancer stromal fibroblasts in the primary tumour site associated with lymph node metastasis: A systematic review including our case series. Biosci Rep. 2013, 33, e00085. [CrossRef] [PubMed].
40. Sugimoto, H.; Mundel, T.M.; Kieran, M.W.; Kalluri, R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol. Ther. 2006, 5, 1640-1646. [CrossRef] [PubMed].
41. Singer, C.F.; Gschwantler-Kaulich, D.; Fink-Retter, A.; Haas, C.; Hudelist, G.; Czerwenka, K.; Kubista, E. Differential gene expression profile in breast cancer-derived stromal fibroblasts. Breast Cancer Res. Treat. 2008, 110, 273-281. [CrossRef] [PubMed].
42. Bauer, M.; Su, G.; Casper, C.; He, R.; Rehrauer,W.; Friedl, A. Heterogeneity of gene expression in stromal fibroblasts of human breast carcinomas and normal breast. Oncogene 2010, 29, 1732-1740. [CrossRef] [PubMed].
43. Tchou, J.; Kossenkov, A.V.; Chang, L.; Satija, C.; Herlyn, M.; Showe, L.C.; Pure, E. Human breast cancer-associated fibroblasts exhibit subtype specific gene expression profiles. BMC Med. Genom. 2012, 5, 39. [CrossRef] [PubMed].
44. Campos, L.T.; Brentani, H.; Roela, R.A.; Katayama, M.L.; Lima, L.; Rolim, C.F.; Milani, C.; Folgueira, M.A.; Brentani, M.M. Differences in transcriptional effects of 1a,25 dihydroxyvitamin D3 on fibroblasts associated to breast carcinomas and from paired normal breast tissues. J. Steroid Biochem. Mol. Biol. 2013, 133, 12-24. [CrossRef] [PubMed].
45. Fleming, J.M.; Miller, T.C.; Quinones, M.; Xiao, Z.; Xu, X.; Meyer, M.J.; Ginsburg, E.; Veenstra, T.D.; Vonderhaar, B.K. The normal breast microenvironment of premenopausal women differentially influences the behavior of breast cancer cells in vitro and in vivo. BMC Med. 2010, 8, 27. [CrossRef] [PubMed].
46. Bergamaschi, A.; Tagliabue, E.; Sorlie, T.; Naume, B.; Triulzi, T.; Orlandi, R.; Russnes, H.G.; Nesland, J.M.; Tammi, R.; Auvinen, P.; et al. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J. Pathol. 2008, 214, 357-367. [CrossRef] [PubMed].
47. Finak, G.; Bertos, N.; Pepin, F.; Sadekova, S.; Souleimanova, M.; Zhao, H.; Chen, H.; Omeroglu, G.; Meterissian, S.; Omeroglu, A.; et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 2008, 14, 518-527. [CrossRef] [PubMed].
48. Fiegl, H.; Millinger, S.; Goebel, G.; Muller-Holzner, E.; Marth, C.; Laird, P.W.; Widschwendter, M. Breast cancer DNA methylation profiles in cancer cells and tumor stroma: Association with HER-2/neu status in primary breast cancer. Cancer Res. 2006, 66, 29-33. [CrossRef] [PubMed].
49. Hu, M.; Yao, J.; Cai, L.; Bachman, K.E.; van den Brule, F.; Velculescu, V.; Polyak, K. Distinct epigenetic changes in the stromal cells of breast cancers. Nat. Genet. 2005, 37, 899-905. [CrossRef] [PubMed].
50. Tyan, S.W.; Hsu, C.H.; Peng, K.L.; Chen, C.C.; Kuo, W.H.; Lee, E.Y.; Shew, J.Y.; Chang, K.J.; Juan, L.J.; Lee,W.H. Breast cancer cells induce stromal fibroblasts to secrete adamts1 for cancer invasion through an epigenetic change. PLoS ONE 2012, 7, e35128. [CrossRef] [PubMed].
51. Ronnov-Jessen, L.; Petersen, O.W.; Koteliansky, V.E.; Bissell, M.J. The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J. Clin. Investig. 1995, 95, 859-873. [CrossRef] [PubMed].
52. Kojima, Y.; Acar, A.; Eaton, E.N.; Mellody, K.T.; Scheel, C.; Ben-Porath, I.; Onder, T.T.; Wang, Z.C.; Richardson, A.L.; Weinberg, R.A.; et al. Autocrine TGF- and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc. Natl. Acad. Sci. USA 2010, 107, 20009-20014. [CrossRef] [PubMed].
53. Mishra, P.J.; Mishra, P.J.; Humeniuk, R.; Medina, D.J.; Alexe, G.; Mesirov, J.P.; Ganesan, S.; Glod, J.W.; Banerjee, D. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res. 2008, 68, 4331-4339. [CrossRef] [PubMed].
54. Weber, C.E.; Kothari, A.N.;Wai, P.Y.; Li, N.Y.; Driver, J.; Zapf, M.A.; Franzen, C.A.; Gupta, G.N.; Osipo, C.; Zlobin, A.; et al. Osteopontin mediates an MZF1-TGF-α1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer. Oncogene 2015, 34, 4821-4833. [CrossRef] [PubMed].
55. Potenta, S.; Zeisberg, E.; Kalluri, R. The role of endothelial-to-mesenchymal transition in cancer progression. Br. J. Cancer 2008, 99, 1375-1379. [CrossRef] [PubMed].
56. Zeisberg, E.M.; Potenta, S.; Xie, L.; Zeisberg, M.; Kalluri, R. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res. 2007, 67, 10123-10128. [CrossRef] [PubMed].
57. Romer, A.M.; Luhr, I.; Klein, A.; Friedl, A.; Sebens, S.; Rosel, F.; Arnold, N.; Strauss, A.; Jonat,W.; Bauer, M. Normal mammary fibroblasts induce reversion of the malignant phenotype in human primary breast cancer. Anticancer Res. 2013, 33, 1525-1536. [PubMed].
58. Shekhar, M.P.; Werdell, J.; Santner, S.J.; Pauley, R.J.; Tait, L. Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: Implications for tumor development and progression. Cancer Res. 2001, 61, 1320-1326. [PubMed].
59. Sadlonova, A.; Novak, Z.; Johnson, M.R.; Bowe, D.B.; Gault, S.R.; Page, G.P.; Thottassery, J.V.;Welch, D.R.; Frost, A.R. Breast fibroblasts modulate epithelial cell proliferation in three-dimensional in vitro co-culture. Breast Cancer Res. 2005, 7, R46-R59. [CrossRef] [PubMed].
60. Dumont, N.; Liu, B.; Defilippis, R.A.; Chang, H.; Rabban, J.T.; Karnezis, A.N.; Tjoe, J.A.; Marx, J.; Parvin, B.; Tlsty, T.D. Breast fibroblasts modulate early dissemination, tumorigenesis, and metastasis through alteration of extracellular matrix characteristics. Neoplasia 2013, 15, 249-262. [CrossRef] [PubMed].
61. Hu, M.; Yao, J.; Carroll, D.K.; Weremowicz, S.; Chen, H.; Carrasco, D.; Richardson, A.; Violette, S.; Nikolskaya, T.; Nikolsky, Y.; et al. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 2008, 13, 394-406. [CrossRef] [PubMed].
62. Hu, M.; Peluffo, G.; Chen, H.; Gelman, R.; Schnitt, S.; Polyak, K. Role of cox-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proc. Natl. Acad. Sci. USA 2009, 106, 3372-3377. [CrossRef] [PubMed].
63. Holliday, D.L.; Brouilette, K.T.; Markert, A.; Gordon, L.A.; Jones, J.L. Novel multicellular organotypic models of normal and malignant breast: Tools for dissecting the role of the microenvironment in breast cancer progression. Breast Cancer Res. 2009, 11, R3. [CrossRef] [PubMed].
64. Krtolica, A.; Parrinello, S.; Lockett, S.; Desprez, P.Y.; Campisi, J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: A link between cancer and aging. Proc. Natl. Acad. Sci. USA 2001, 98, 12072-12077. [CrossRef] [PubMed].
65. Kuperwasser, C.; Chavarria, T.;Wu, M.; Magrane, G.; Gray, J.W.; Carey, L.; Richardson, A.;Weinberg, R.A. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc. Natl. Acad. Sci. USA 2004, 101, 4966-4971. [CrossRef] [PubMed].
66. Martens, J.W.; Sieuwerts, A.M.; Bolt-deVries, J.; Bosma, P.T.; Swiggers, S.J.; Klijn, J.G.; Foekens, J.A. Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression. Thromb. Haemost. 2003, 89, 393-404. [PubMed].
67. Palmieri, C.; Roberts-Clark, D.; Assadi-Sabet, A.; Coope, R.C.; O'Hare, M.; Sunters, A.; Hanby, A.; Slade, M.J.; Gomm, J.J.; Lam, E.W.; et al. Fibroblast growth factor 7, secreted by breast fibroblasts, is an interleukin-1α-induced paracrine growth factor for human breast cells. J. Endocrinol. 2003, 177, 65-81. [CrossRef] [PubMed].
68. Scherz-Shouval, R.; Santagata, S.; Mendillo, M.L.; Sholl, L.M.; Ben-Aharon, I.; Beck, A.H.; Dias-Santagata, D.; Koeva, M.; Stemmer, S.M.; Whitesell, L.; et al. The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy. Cell 2014, 158, 564-578. [CrossRef] [PubMed].
69. Jiang,W.G.; Martin, T.A.; Parr, C.; Davies, G.; Matsumoto, K.; Nakamura, T. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit. Rev. Oncol. Hematol. 2005, 53, 35-69. [CrossRef] [PubMed].
70. Orimo, A.; Gupta, P.B.; Sgroi, D.C.; Arenzana-Seisdedos, F.; Delaunay, T.; Naeem, R.; Carey, V.J.; Richardson, A.L.; Weinberg, R.A. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121, 335-348. [CrossRef] [PubMed].
71. Barone, I.; Catalano, S.; Gelsomino, L.; Marsico, S.; Giordano, C.; Panza, S.; Bonofiglio, D.; Bossi, G.; Covington, K.R.; Fuqua, S.A.; et al. Leptin mediates tumor-stromal interactions that promote the invasive growth of breast cancer cells. Cancer Res. 2012, 72, 1416-1427. [CrossRef] [PubMed].
72. Hugo, H.J.; Lebret, S.; Tomaskovic-Crook, E.; Ahmed, N.; Blick, T.; Newgreen, D.F.; Thompson, E.W.; Ackland, M.L. Contribution of fibroblast and mast cell (afferent) and tumor (efferent) IL-6 effects within the tumor microenvironment. Cancer Microenviron. 2012, 5, 83-93. [CrossRef] [PubMed].
73. Adams, E.F.; Newton, C.J.; Braunsberg, H.; Shaikh, N.; Ghilchik, M.; James, V.H. Effects of human breast fibroblasts on growth and 17 α-estradiol dehydrogenase activity of MCF-7 cells in culture. Breast Cancer Res. Treat. 1988, 11, 165-172. [CrossRef] [PubMed].
74. Chang, P.H.; Hwang-Verslues,W.W.; Chang, Y.C.; Chen, C.C.; Hsiao, M.; Jeng, Y.M.; Chang, K.J.; Lee, E.Y.; Shew, J.Y.; Lee, W.H. Activation of Robo1 signaling of breast cancer cells by Slit2 from stromal fibroblast restrains tumorigenesis via blocking PI3K/Akt/α-catenin pathway. Cancer Res. 2012, 72, 4652-4661. [CrossRef] [PubMed].
75. Xu, K.; Rajagopal, S.; Klebba, I.; Dong, S.; Ji, Y.; Liu, J.; Kuperwasser, C.; Garlick, J.A.; Naber, S.P.; Buchsbaum, R.J. The role of fibroblast Tiam1 in tumor cell invasion and metastasis. Oncogene 2010, 29, 6533-6542. [CrossRef] [PubMed].
76. Pallangyo, C.K.; Ziegler, P.K.; Greten, F.R. IKKα acts as a tumor suppressor in cancer-associated fibroblasts during intestinal tumorigenesis. J. Exp. Med. 2015, 212, 2253-2266. [PubMed].
77. Valastyan, S.; Weinberg, R.A. Tumor metastasis: Molecular insights and evolving paradigms. Cell 2011, 147, 275-292. [CrossRef] [PubMed].
78. Sethi, N.; Kang, Y. Unravelling the complexity of metastasis-Molecular understanding and targeted therapies. Nat. Rev. Cancer 2011, 11, 735-748. [CrossRef] [PubMed].
79. Hay, E.D. The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it. Dev. Dyn. 2005, 233, 706-720. [CrossRef] [PubMed].
80. Thiery, J.P. Epithelial-mesenchymal transitions in development and pathologies. Curr. Opin. Cell. Biol. 2003, 15, 740-746. [CrossRef] [PubMed].
81. Mani, S.A.; Guo, W.; Liao, M.J.; Eaton, E.N.; Ayyanan, A.; Zhou, A.Y.; Brooks, M.; Reinhard, F.; Zhang, C.C.; Shipitsin, M.; et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133, 704-715. [CrossRef] [PubMed].
82. Gao, M.Q.; Kim, B.G.; Kang, S.; Choi, Y.P.; Park, H.; Kang, K.S.; Cho, N.H. Stromal fibroblasts from the interface zone of human breast carcinomas induce an epithelial-mesenchymal transition-like state in breast cancer cells in vitro. J. Cell. Sci. 2010, 123, 3507-3514. [CrossRef] [PubMed].
83. Soon, P.S.; Kim, E.; Pon, C.K.; Gill, A.J.; Moore, K.; Spillane, A.J.; Benn, D.E.; Baxter, R.C. Breast cancer-associated fibroblasts induce epithelial-to-mesenchymal transition in breast cancer cells. Endocr. Relat. Cancer 2013, 20, 1-12. [CrossRef] [PubMed].
84. Yu, Y.; Xiao, C.H.; Tan, L.D.; Wang, Q.S.; Li, X.Q.; Feng, Y.M. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-α signalling. Br. J. Cancer 2014, 110, 724-732. [CrossRef] [PubMed].
85. Humphries, B.; Yang, C. The microRNA-200 family: Small molecules with novel roles in cancer development, progression and therapy. Oncotarget 2015, 6, 6472-6498. [CrossRef] [PubMed].
86. Tang, X.; Hou, Y.; Yang, G.; Wang, X.; Tang, S.; Du, Y.E.; Yang, L.; Yu, T.; Zhang, H.; Zhou, M.; et al. Stromal miR-200s contribute to breast cancer cell invasion through CAF activation and ECM remodeling. Cell. Death Differ. 2016, 23, 132-145. [CrossRef] [PubMed].
87. Hayflick, L. The limited in vitro lifetime of human diploid cell strains. Exp. Cell. Res. 1965, 37, 614-636. [CrossRef].
88. Krtolica, A.; Campisi, J. Cancer and aging: A model for the cancer promoting effects of the aging stroma. Int. J. Biochem. Cell. Biol. 2002, 34, 1401-1414. [CrossRef].
89. Castro, P.; Giri, D.; Lamb, D.; Ittmann, M. Cellular senescence in the pathogenesis of benign prostatic hyperplasia. Prostate 2003, 55, 30-38. [CrossRef] [PubMed].
90. Yang, G.; Rosen, D.G.; Zhang, Z.; Bast, R.C., Jr.; Mills, G.B.; Colacino, J.A.; Mercado-Uribe, I.; Liu, J. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc. Natl. Acad. Sci. USA 2006, 103, 16472-16477. [CrossRef] [PubMed].
91. Liu, J.; Xu, K.; Chase, M.; Ji, Y.; Logan, J.K.; Buchsbaum, R.J. Tiam1-regulated osteopontin in senescent fibroblasts contributes to the migration and invasion of associated epithelial cells. J. Cell. Sci. 2012, 125, 376-386. [CrossRef] [PubMed].
92. Choi, Y.P.; Lee, J.H.; Gao, M.Q.; Kim, B.G.; Kang, S.; Kim, S.H.; Cho, N.H. Cancer-associated fibroblast promote transmigration through endothelial brain cells in three-dimensional in vitro models. Int. J. Cancer 2014, 135, 2024-2033. [CrossRef] [PubMed].
93. Fidler, I.J. The pathogenesis of cancer metastasis: The "seed and soil" hypothesis revisited. Nat. Rev. Cancer 2003, 3, 453-458. [CrossRef] [PubMed].
94. Zhang, X.H.; Jin, X.; Malladi, S.; Zou, Y.; Wen, Y.H.; Brogi, E.; Smid, M.; Foekens, J.A.; Massague, J. Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. Cell 2013, 154, 1060-1073. [CrossRef] [PubMed].
95. Duda, D.G.; Duyverman, A.M.; Kohno, M.; Snuderl, M.; Steller, E.J.; Fukumura, D.; Jain, R.K. Malignant cells facilitate lung metastasis by bringing their own soil. Proc. Natl. Acad. Sci. USA 2010, 107, 21677-21682. [CrossRef] [PubMed].
96. Nishida, N.; Yano, H.; Nishida, T.; Kamura, T.; Kojiro, M. Angiogenesis in cancer. Vasc. Health Risk Manag. 2006, 2, 213-219. [CrossRef] [PubMed].
97. Gharbaran, R. Advances in the molecular functions of syndecan-1 (SDC1/CD138) in the pathogenesis of malignancies. Crit. Rev. Oncol. Hematol. 2015, 94, 1-17. [CrossRef] [PubMed].
98. Maeda, T.; Alexander, C.M.; Friedl, A. Induction of syndecan-1 expression in stromal fibroblasts promotes proliferation of human breast cancer cells. Cancer Res. 2004, 64, 612-621. [CrossRef] [PubMed].
99. Maeda, T.; Desouky, J.; Friedl, A. Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis. Oncogene 2006, 25, 1408-1412. [CrossRef] [PubMed].
100. He, Y.; Karpanen, T.; Alitalo, K. Role of lymphangiogenic factors in tumor metastasis. Biochim. Biophys. Acta 2004, 1654, 3-12. [CrossRef] [PubMed].
101. Salven, P.; Mustjoki, S.; Alitalo, R.; Alitalo, K.; Rafii, S. VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. Blood 2003, 101, 168-172. [CrossRef] [PubMed].
102. Skobe, M.; Hawighorst, T.; Jackson, D.G.; Prevo, R.; Janes, L.; Velasco, P.; Riccardi, L.; Alitalo, K.; Claffey, K.; Detmar, M. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 2001, 7, 192-198. [CrossRef] [PubMed].
103. Ran, S.; Volk, L.; Hall, K.; Flister, M.J. Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology 2010, 17, 229-251. [CrossRef] [PubMed].
104. Laurent, T.C.; Fraser, J.R. Hyaluronan. FASEB J. 1992, 6, 2397-2404. [PubMed].
105. Turley, E.A.; Noble, P.W.; Bourguignon, L.Y. Signaling properties of hyaluronan receptors. J. Biol. Chem. 2002, 277, 4589-4592. [CrossRef] [PubMed].
106. Koyama, H.; Kobayashi, N.; Harada, M.; Takeoka, M.; Kawai, Y.; Sano, K.; Fujimori, M.; Amano, J.; Ohhashi, T.; Kannagi, R.; et al. Significance of tumor-associated stroma in promotion of intratumoral lymphangiogenesis: Pivotal role of a hyaluronan-rich tumor microenvironment. Am. J. Pathol. 2008, 172, 179-193. [CrossRef] [PubMed].
107. Liao, D.; Luo, Y.; Markowitz, D.; Xiang, R.; Reisfeld, R.A. Cancer-associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS ONE 2009, 4, e7965. [CrossRef] [PubMed].
108. Unsworth, A.; Anderson, R.; Britt, K. Stromal fibroblasts and the immune microenvironment: Partners in mammary gland biology and pathology? J. Mammary Gland Biol. Neoplasia 2014, 19, 169-182. [CrossRef] [PubMed].
109. Guy, C.T.; Cardiff, R.D.; Muller,W.J. Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease. Mol. Cell. Biol. 1992, 12, 954-961. [CrossRef] [PubMed].
110. Erez, N.; Truitt, M.; Olson, P.; Arron, S.T.; Hanahan, D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell. 2010, 17, 135-147. [CrossRef] [PubMed].
111. Ksiazkiewicz, M.; Gottfried, E.; Kreutz, M.; Mack, M.; Hofstaedter, F.; Kunz-Schughart, L.A. Importance of CCL2-CCR2A/2B signaling for monocyte migration into spheroids of breast cancer-derived fibroblasts. Immunobiology 2010, 215, 737-747. [CrossRef] [PubMed].
112. Fang, W.B.; Jokar, I.; Chytil, A.; Moses, H.L.; Abel, T.; Cheng, N. Loss of one Tgfbr2 allele in fibroblasts promotes metastasis in MMTV: Polyoma middle t transgenic and transplant mouse models of mammary tumor progression. Clin. Exp. Metastasis 2011, 28, 351-366. [CrossRef] [PubMed].
113. Shevde, L.A.; Samant, R.S. Role of osteopontin in the pathophysiology of cancer. Matrix Biol. 2014, 37, 131-141. [CrossRef] [PubMed].
114. Sharon, Y.; Raz, Y.; Cohen, N.; Ben-Shmuel, A.; Schwartz, H.; Geiger, T.; Erez, N. Tumor-derived osteopontin reprograms normal mammary fibroblasts to promote inflammation and tumor growth in breast cancer. Cancer Res. 2015, 75, 963-973. [CrossRef] [PubMed].
115. Pavlides, S.; Vera, I.; Gandara, R.; Sneddon, S.; Pestell, R.G.; Mercier, I.; Martinez-Outschoorn, U.E.; Whitaker-Menezes, D.; Howell, A.; Sotgia, F.; et al. Warburg meets autophagy: Cancer-associated fibroblasts accelerate tumor growth and metastasis via oxidative stress, mitophagy, and aerobic glycolysis. Antioxid. Redox Signal. 2012, 16, 1264-1284. [CrossRef] [PubMed].
116. Codogno, P.; Meijer, A.J. Autophagy and signaling: Their role in cell survival and cell death. Cell. Death Differ. 2005, 12, 1509-1518. [CrossRef] [PubMed].
117. Zhang, H.; Bosch-Marce, M.; Shimoda, L.A.; Tan, Y.S.; Baek, J.H.;Wesley, J.B.; Gonzalez, F.J.; Semenza, G.L. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J. Biol. Chem. 2008, 283, 10892-10903. [CrossRef] [PubMed].
118. Pavlides, S.; Whitaker-Menezes, D.; Castello-Cros, R.; Flomenberg, N.; Witkiewicz, A.K.; Frank, P.G.; Casimiro, M.C.; Wang, C.; Fortina, P.; Addya, S.; et al. The reverse warburg effect: Aerobic glycolysis in cancer-associated fibroblasts and the tumor stroma. Cell Cycle 2009, 8, 3984-4001. [CrossRef] [PubMed].
119. Pavlides, S.; Tsirigos, A.; Vera, I.; Flomenberg, N.; Frank, P.G.; Casimiro, M.C.; Wang, C.; Fortina, P.; Addya, S.; Pestell, R.G.; et al. Loss of stromal caveolin-1 leads to oxidative stress, mimics hypoxia and drives inflammation in the tumor microenvironment, conferring the "reverse warburg effect": A transcriptional informatics analysis with validation. Cell Cycle 2010, 9, 2201-2219. [CrossRef] [PubMed].
120. Martinez-Outschoorn, U.E.; Balliet, R.M.; Rivadeneira, D.B.; Chiavarina, B.; Pavlides, S.; Wang, C.; Whitaker-Menezes, D.; Daumer, K.M.; Lin, Z.;Witkiewicz, A.K.; et al. Oxidative stress in cancer-associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle 2010, 9, 3256-3276. [CrossRef] [PubMed].
121. Guido, C.; Whitaker-Menezes, D.; Capparelli, C.; Balliet, R.; Lin, Z.; Pestell, R.G.; Howell, A.; Aquila, S.; Ando, S.; Martinez-Outschoorn, U.; et al. Metabolic reprogramming of cancer-associated fibroblasts by TGF-beta drives tumor growth: Connecting TGF-α signaling with "warburg-like" cancer metabolism and l-lactate production. Cell Cycle 2012, 11, 3019-3035. [CrossRef] [PubMed].
122. Pontiggia, O.; Sampayo, R.; Raffo, D.; Motter, A.; Xu, R.; Bissell, M.J.; Joffe, E.B.; Simian, M. The tumor microenvironment modulates tamoxifen resistance in breast cancer: A role for soluble stromal factors and fibronectin through α1 integrin. Breast Cancer Res. Treat. 2012, 133, 459-471. [CrossRef] [PubMed].
123. Shekhar, M.P.; Santner, S.; Carolin, K.A.; Tait, L. Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity. Am. J. Pathol. 2007, 170, 1546-1560. [CrossRef] [PubMed].
124. Luo, H.; Yang, G.; Yu, T.; Luo, S.; Wu, C.; Sun, Y.; Liu, M.; Tu, G. Gper-mediated proliferation and estradiol production in breast cancer-associated fibroblasts. Endocr. Relat. Cancer 2014, 21, 355-369. [CrossRef] [PubMed].
125. Martinez-Outschoorn, U.E.; Goldberg, A.; Lin, Z.; Ko, Y.H.; Flomenberg, N.; Wang, C.; Pavlides, S.; Pestell, R.G.; Howell, A.; Sotgia, F.; et al. Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biol. Ther. 2011, 12, 924-938. [CrossRef] [PubMed].
126. Amornsupak, K.; Insawang, T.; Thuwajit, P.; P, O.C.; Eccles, S.A.; Thuwajit, C. Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells. BMC Cancer 2014, 14, 955. [CrossRef] [PubMed].
127. Hiscox, S.; Jordan, N.J.; Jiang,W.; Harper, M.; McClelland, R.; Smith, C.; Nicholson, R.I. Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: Implications for tumour-stroma interactions. Endocr. Relat. Cancer 2006, 13, 1085-1099. [CrossRef] [PubMed].
128. Baselga, J.; Albanell, J.; Ruiz, A.; Lluch, A.; Gascon, P.; Guillem, V.; Gonzalez, S.; Sauleda, S.; Marimon, I.; Tabernero, J.M.; et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J. Clin. Oncol. 2005, 23, 5323-5333. [CrossRef] [PubMed].
129. Tan, A.R.; Yang, X.; Hewitt, S.M.; Berman, A.; Lepper, E.R.; Sparreboom, A.; Parr, A.L.; Figg, W.D.; Chow, C.; Steinberg, S.M.; et al. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J. Clin. Oncol. 2004, 22, 3080-3090. [CrossRef] [PubMed].
130. Mueller, K.L.; Madden, J.M.; Zoratti, G.L.; Kuperwasser, C.; List, K.; Boerner, J.L. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of met. Breast Cancer Res. 2012, 14, R104. [CrossRef] [PubMed].
131. Dittmer, A.; Fuchs, A.; Oerlecke, I.; Leyh, B.; Kaiser, S.; Martens, J.W.; Lutzkendorf, J.; Muller, L.; Dittmer, J. Mesenchymal stem cells and carcinoma-associated fibroblasts sensitize breast cancer cells in 3D cultures to kinase inhibitors. Int. J. Oncol. 2011, 39, 689-696. [CrossRef] [PubMed].